Inflammatory Basis of Pulmonary Arterial Hypertension Implications for Perioperative and Critical Care Medicine
Pulmonary hypertension, defined as a resting mean pulmonary artery pressure greater than or equal to 25 mmHg, results from a myriad of conditions. The Fifth World Symposium on Pulmonary Hypertension proposed a classification system that organizes pulmonary hypertension into five groups based on common hemodynamic, pathophysiologic, and therapeutic parameters.1 This review focuses on pulmonary arterial hypertension (Group 1 pulmonary hypertension), a disease in which progressive pulmonary vascular obstruction, remodeling, and destruction lead to increased right ventricular afterload and hypertrophy, right heart failure, and death. On a cellular level, the dysregulated proliferation of endothelial, smooth muscle, and immune cells predominates within the diseased vessels.2 Hemodynamically, pulmonary arterial hypertension can be defined as a mean pulmonary artery pressure greater than 25 mmHg, a pulmonary capillary wedge pressure less than 15 mmHg, and a pulmonary vascular resistance (PVR) greater than 3 Wood units in the absence of a more common cause such as left heart disease, chronic venothromboembolic disease, or lung disease. Like pulmonary hypertension in general, pulmonary arterial hypertension can result from multiple causes, including infectious and autoimmune pathologies. In this review, our focus will be on pulmonary arterial hypertension specifically (World Health Organization Group 1), predominantly comprising idiopathic and heritable pulmonary arterial hypertension...
Conclusions: The results indicated that the incidence of pemphigus is remarkably high in the Eastern region of Turkey and the associated factors including lifestyle changes should be taken into mind when considering these patients. PMID: 31616221 [PubMed]
Conclusions: It appears that further studies are necessary to explain this problem, perhaps to include an evaluation of TF levels in psoriatic skin. PMID: 31616219 [PubMed]
Authors: Kamińska-Winciorek G, Cybulska-Stopa B, Lugowska I, Ziobro M, Rutkowski P Abstract The introduction of immunotherapy into the treatment of cancer patients has revolutionised the oncological approach and significantly improved patient survival. The key drugs are immune checkpoint inhibitors (CPIs), whose mechanism of action is to elicit immune response against cancer cell antigens. Three types of CPIs are currently used and approved: an anti-CTLA-4 antibody, ipilimumab; anti-PD-1 antibodies, nivolumab and pembrolizumab; and anti-PD-L1 antibodies: atezolizumab, avelumab and durvalumab. CPIs have been widely...
In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, whom received apatinib (250mg or 500mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second- or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rat...
PMID: 31613809 [PubMed - in process]
PMID: 31613808 [PubMed - in process]
PMID: 31613807 [PubMed - in process]
PMID: 31613806 [PubMed - in process]
PMID: 31613805 [PubMed - in process]
PMID: 31613804 [PubMed - in process]